Group 1 - The company, Puhua International (01355.HK), announced a conditional sale agreement with Zheng Tong, where the buyer, Jiayi Global Limited, will purchase 100% of the issued share capital of the target company, Ono Hong Kong Limited, for a total consideration of HKD 22 million [1] - Upon completion, Ono Hong Kong Limited will become an indirect wholly-owned subsidiary of the company, and the company will hold a 37.5% equity interest in Beisheng Biotechnology, with its financial performance, assets, and liabilities accounted for using the equity method in the group's financial statements [1] Group 2 - The company believes that the research and development of proprietary rights and technologies related to healthcare and beauty businesses is key to gaining a competitive advantage [2] - Current R&D focus areas include: (a) Type III collagen-hyaluronic acid "dual protein" water light needle, utilizing hyaluronic acid permeation enhancement technology to improve transdermal absorption efficiency; (b) Hydroxyapatite/collagen composite fillers targeting the large market for temporal fillers; (c) Photoelectric activated collagen repair essence aimed at developing essence containing thermosensitive/photo-sensitive liposomes for precise repair; and (d) Stem cell exosome targeted anti-aging therapy focusing on developing freeze-dried exosome microspheres for targeted release and long-lasting repair [2]
朸浚国际(01355.HK)附属拟2200万港元收购奥诺香港100%股权